# Abaloparatide

Canonical source: https://retacompare.com/encyclopedia/abaloparatide

Selective PTH1R agonist with bias toward the transient (RG) receptor conformation, producing more anabolic, less resorptive bone signaling than Teriparatide.

Reference facts

Also known asTymlos, BA058CategoryBone & CalciumMechanism of actionSelective PTH1R agonist with bias toward the transient (RG) receptor conformation, producing more anabolic, less resorptive bone signaling than Teriparatide.TargetsPTH1R (RG-biased)Indications under research or approvedPostmenopausal osteoporosis (high fracture risk)Regulatory status (reference entry)FDA-approved (2017)Half-life~1.7 hoursSequenceAVSEHQLLHDKGKSIQDLRRRELLEKLLAKKLAHSequence notes34-residue PTHrP analog with multiple substitutions for selective PTH1R RG conformation activation.Molecular weight (Da)3961Originator / sponsorRadius HealthFirst reported2008
    Primary References

ACTIVE trial, Miller et al., JAMA 2016


    Explore research articles about Abaloparatide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- ACTIVE trial, Miller et al., JAMA 2016: https://pubmed.ncbi.nlm.nih.gov/27532898/